GlassScriptPhysician profile
Yevgeny Mironer
NPI 1992728141
$5,723.28
in general payments reported to CMS, 2019-2025
34 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $1,038 · 2021: $1,252 · 2022: $733 · 2023: $1,451 · 2024: $23.15 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,605.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,638.45 | 2019-2025 | Eterna, Octrode |
| Nevro Corp. | $867.49 | 2022-2023 | Senza |
| Boston Scientific Corporation | $655.51 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.26 | 2019-2022 | |
| Medtronic, INC. | $201.73 | 2022-2024 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $183.80 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.32 | 2019-2020 | |
| Forte Bio-Pharma LLC | $136.38 | 2019-2021 | |
| Fidia Pharma USA INC. | $79.65 | 2019 | |
| Grt US Holding, INC. | $60.09 | 2022 | |
| Arbor Pharmaceuticals, INC. | $53.42 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $52.65 | 2019-2020 | |
| Pfizer INC. | $49.15 | 2019-2020 | |
| Almatica Pharma LLC | $36.98 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $30.71 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.88 | 2019 | |
| Spr Therapeutics, INC | $20.13 | 2020 | |
| Si-Bone, INC. | $19.36 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.90 | 2022 | |
| Eisai INC. | $15.40 | 2021 | |
| Novo Nordisk INC | $15.32 | 2019 | |
| Stimwave Technologies Incorporated | $14.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.35 | 2019 | |
| Biodelivery Sciences International, INC. | $14.20 | 2019 | |
| Nalu Medical, INC. | $13.60 | 2021 | |
| Ibsa Pharma INC. | $13.53 | 2020 | |
| Zimmer Biomet Holdings, INC. | $13.23 | 2019 | |
| Shionogi INC | $13.07 | 2019 | |
| Virtus Pharmaceuticals LLC | $11.49 | 2021 | |
| Mdd US Operations, LLC | $10.82 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yevgeny Mironer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.